S. E. Reese

发表

Nearly 100,000 miles of pipelines planned or underway worldwide

S. E. Reese, 1975 .

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

William F. Fadel, S. E. Reese, M. Stockwell, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Landlocked Fall Chinook Salmon Sperm Motility after Short Term Milt Storage

S. E. Reese, M. E. Barnes, A. J. Long, 2017 .

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2022, MMWR. Morbidity and mortality weekly report.

Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, medRxiv.

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, BMJ.

Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—Nine States, January–September 2021

S. E. Reese, C. Mcevoy, S. Schrag, 2021, American Journal of Transplantation.

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021.

William F. Fadel, S. E. Reese, C. Mcevoy, 2021, MMWR. Morbidity and mortality weekly report.

Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022.

S. E. Reese, C. Mcevoy, P. Embí, 2022, The Journal of infectious diseases.

Accuracy of COVID-19–Like Illness Diagnoses in Electronic Health Record Data: Retrospective Cohort Study

S. E. Reese, C. Mcevoy, Andrea Steffens, 2022, JMIR formative research.

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Associations between ABO non‐identical platelet transfusions and patient outcomes—A multicenter retrospective analysis

S. E. Reese, S. Kleinman, E. Hod, 2023, Transfusion.

Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods

William F. Fadel, S. E. Reese, C. Mcevoy, 2023, JAMA network open.

Effectiveness of COVID-19 Vaccines at Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompromised Adults: An Observational Study of Real-World Data Across 10 US States from August-December 2021

S. E. Reese, C. Mcevoy, P. Embí, 2022, medRxiv.

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2023, MMWR. Morbidity and mortality weekly report.

Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents.

S. E. Reese, M. Stockwell, R. Link-Gelles, 2023, Pediatrics.

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2023, MMWR. Morbidity and mortality weekly report.

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2023, American Journal of Transplantation.

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023

William F. Fadel, S. E. Reese, C. Mcevoy, 2023, MMWR. Morbidity and mortality weekly report.

Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months–5 Years — VISION Network, United States, July 2022–June 2023

S. E. Reese, M. Stockwell, R. Link-Gelles, 2023, MMWR. Morbidity and mortality weekly report.

Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design

S. E. Reese, R. Link-Gelles, S. Grannis, 2023, Vaccine.